Contralateral breast cancer: Factors associated with stage and size at presentation

Breast Journal

Volumn 10, Issue 4, 2004, Pages 304-312

  Mertens, Wilson C ^a,b,c   Hilbert, Veronica ^a   Makari Judson, Grace ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYSTATE HEALTH   (United States)

Author keywords

Contralateral breast cancer; Mammography; Screening; Tumor size; Tumor stage

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CONTRALATERAL BREAST CANCER; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ONSET AGE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; REGRESSION ANALYSIS; RISK FACTORS;

EID: 3142764634     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.21333.x     Document Type: Article

References (47)

1. Horn PL, Thompson WD, Schwartz SM. Factors associated with the risk of second primary breast cancer: an analysis of data from the Connecticut tumor registry. J Chronic Dis 1987;40:1003-11.
2. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-1982. Natl Cancer Inst Monogr 1985;68:99-112.
3. Ewertz M, Mouridsen HT. Second cancer following cancer of the female breast in Denmark, 1943-1980. Natl Cancer Inst Monogr 1985;68:325-29.
4. Schwartz AG, Ragheb NE, Swanson GM, Satariano WA. Racial and age differences in multiple primary cancers after breast cancer: a population-based analysis. Breast Cancer Res Treat 1989;14:245-54.
5. Horn PL, Thompson WD. Risk of contralateral breast cancer: associations with histologic, clinical, and therapeutic factors. Cancer 1988;62:412-24.
6. Horn PL, Thompson WD. Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol 1988;128:309-23.
7. Leis HP. Managing the remaining breast. Cancer 1980;46:1026-30.
8. Ringberg A, Palmer B, Linell F. The contralateral breast at reconstructive surgery after breast cancer operation: a histopathological study. Breast Cancer Res Treat 1982;2:151-61.
9. Guiss LW. The problem of bilateral independent mammary carcinoma. Am J Surg 1954;88:171-77.
10. Urban JA. Bilateral breast cancer. Cancer 1969;24:1310-13.
11. Neilsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy. Cancer 1984;54:612-15.
12. Arriagada R, Rutqvist LE, Kramer A, Johansson H. Competing risks determining event-free survival in early breast cancer. Br J Cancer 1992;66:951-57.
13. Gajalakshmi CK, Shanta V, Hakama M. Risk factors for contralateral breast cancer in Chennai (Madras). India Int J Epidemiol 1998;27:743-50.
14. Adami HO, Bergstrom R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cancer 1985;55:643-47.
15. Bernstein JL, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 1992;136:925-36.
16. Cook LS, White E, Schwartz SM, et al. A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Cause Control 1996;7:382-90.
17. Gogas J, Markopoulos C, Skandalakis P, Gogas H. Bilateral breast cancer. Am Surg 1993;59:733-35.
18. Kelmendi de Ustaran J, Meiss RP. Primary synchronous bilateral breast cancer: epidemiological approach. Breast Cancer Res Treat 1988;12:311-14.
19. Lewis TR, Casey J, Buerk CA, Cammack KV. Incidence of lobular carcinoma in bilateral breast cancer. Am J Surg 1982;144:634-38.
20. Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 1995;13:1578-83.
21. Rutqvist LE, Cedermark B, Glas U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991;18:1299-306.
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-67.
23. Gershoni-Baruch R, Dagan E, Fried G, et al. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Eur J Hum Genet 1999;7:833-36.
24. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-16.
25. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1542-649.
26. Burns PE, Dabbs K, May C, et al. Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Can Med Assoc J 1984;130:881-86.
27. Dawson PJ, Maloney T, Gimotty P, et al. Bilateral breast cancer: one disease or two? Breast Cancer Res Treat 1991;19:233-44.
28. de la Rochefordiere A, Asselain B, Scholl S, et al. Simultaneous bilateral breast carcinomas: a retrospective review of 149 cases. Int J Radiat Oncol Biol Phys 1994;30:35-41.
29. Shaw LJ, Iskandrian AE, Hachamovitch R, et al. Evidence-based risk assessment in noninvasive imaging. J Nucl Med 2001;42:1424-36.
30. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
31. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Lifetime Learning Publications, 1982.
32. Akaike H. Factor analysis and AIC. Psychometrica 1974;52:317-32.
33. Healey EA, Cook EF, Orav EJ, et al. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 1993;11:1545-52.
34. Samant RS, Olivotto IA, Jackson JSH, Mates D. Diagnosis of metachronous contralateral breast cancer. Breast J 2001;7:405-10.
35. Abdalla I, Thisted RA, Heinmann R. The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer J 2000;6:266-72.
36. Brenner H, Engelsmann B, Stegmaier C, Ziegler H. Clinical epidemiology of bilateral breast cancer. Cancer 1993;72:3629-35.
37. Gajalakshmi CK, Shanta V, Hakama M. Survival from contralateral breast cancer. Breast Cancer Res Treat 1999;58:115-22.
38. Fracchia AA, Robinson D, Legaspi A, et al. Survival in bilateral breast cancer. Cancer 1985;55:1414-21.
39. Massachusetts Department of Public Health. Springfield, Massachusetts Behavioral Risk Factor Survey 1994-1996. Available at www.state.ma.us/dph/bhsre/ cdsp/spring.htm; accessed April 9, 2003.
40. Women's Health Network. Seven Regions: 2001 Massachusetts Screening Mammography Utilization Report. Boston: Massachusetts Department of Public Health, 2002.
41. Blustein J. Medicare coverage, supplemental insurance, and the use of mammography by older women. N Engl J Med 1995;332:1138-43.
42. Jazieh AR, Soora I. Mammography utilization pattern throughout the state of Arkansas: a challenge for the future. J Commun Health 2001;26:249-55.
43. Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998;338:1089-96.
44. Senofsky GM, Wanebo HJ, Wilhelm MC, et al. Has monitoring of the contralateral breast improved the prognosis in patients treated for primary breast cancer? Cancer 1986;57:597-602.
45. Fisher ER, Fisher B, Sass R, Wickerham L. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4). XI. Bilateral breast cancer. Cancer 1984;54:3002-11.
46. Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2001;93:1008-13.
47. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.